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Abstract 
Purpose: To investigate experimentally the inclusion of artemether into the cavity of hydroxypropyl-β-
cyclodextrin and examine its effect on the solubility and dissolution rate of the drug. 
Methods: Inclusion complexes of artemether with hydroxypropyl-β-cyclodextrin of molar ratios 1:1, 1:2 
and 1:3 were prepared using the kneading method. Phase solubility analysis and in vitro dissolution 
studies were utilized in evaluating the influence of inclusion complex formation on the solubility and 
dissolution rate of the drug. The complexes were characterized using differential scanning calorimetry 
(DSC) and Fourier transform infrared spectroscopy (FT-IR). The inclusion complex containing equimolar 
concentrations of artemether and hydroxypropyl-β-cyclodextrin was then formulated into tablets via 
direct compression and evaluated for various pharmaceutical characteristics including hardness, 
friability, absolute drug content and comparative in vitro dissolution profiles with some commercially 
available brands of artemether. 
Results: The phase solubility diagram for the formed complexes in water at 37 oC indicated a linear 
curve soluble complex system (referred to as the AL system), and a stability constant (KC) value of 143 
M-1. Evidence consistent with inclusion complex formation was obtained using FT-IR and DSC. The 
formulated inclusion complex tablets exhibited a higher rate of dissolution than the pure drug and 
commercial brands, showing 3.9-, 1.8- and 1.6-fold increases, respectively, over a period of 15 min.  
Conclusion: Inclusion complexation of artemether with hydroxypropyl-β-cyclodextrin is a promising 
approach to enhance the solubility and dissolution rate of the drug. 
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All drugs, regardless of their route of 
administration, should exhibit at least limited 
aqueous solubility for therapeutic efficiency. Thus 
relatively insoluble compounds can exhibit erratic 
or incomplete absorption, and it might be 
appropriate to use more soluble salts or chemical 
derivatives. Complexation, solid dispersion or 
micronizing techniques might alternatively be 
employed [1]. Molecular complexation is the 
interaction between “guest” molecules and 
cyclodextrins (CD) to form reversible inclusion 
complex which has been shown to be an 
effective means of increasing the aqueous 
solubility of hydrophobic compounds [2].  
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Cyclodextrins are torus shaped molecules of D-
glucopyranose obtained by the enzymatic 
degradation of starch [2,3]. There are three types 
of natural cyclodextrins – alpha (α), beta (β), and 
gamma (γ) with six, seven and eight 
glucopyranose units, respectively. The 
cyclodextrin cavity dimension, which is important 
for guest-host interaction, ranges from 0.174 to 
0.427 nm for alpha and gamma cyclodextrins 
respectively [2,3].  
 
Inclusion complex formation is mediated majorly 
by van der Waals attraction and hydrophobic 
interaction.  The “host,” includes, totally or partly, 
the hydrophobic molecule [2,3].  
 
Artemether is a potent and rapidly acting 
antimalarial agent available for the treatment of 
severe multi-resistant malaria and is included in 
World Health Organization (W.H.O) list of 
essential medicines [4]. It is active against P. 
vivax as well as chloroquine-sensitive and 
chloroquine-resistant strains of P. falciparum; it is 
also indicated for the treatment of cerebral 
malaria [4]. Unfortunately, this potent blood 
schizonticidal belonging to Class II of 
Biopharmaceutical Classification System shows 
poor water solubility and low bioavailability 
following oral administration [5]. The aim of this 
study is to utilize 2-hydroxypropyl-β-cyclodextrin 
for improving the solubility and dissolution rate of 








weight (Mw) = 1540 (Sigma-Aldrich, U.S.A), CAS 
No. 128446-35-5. A pure sample of artemether 
(Mw = 298.4, Batch No. ATM 121003) was a kind 
donation from Afrab Chem. Nigeria Ltd, Lagos. 
Other reagents and chemicals were of analytical 
reagent grade. 
 
Brand A (Coartem® tablets); Batch No. X1571, 
Manufac. date Jan. 2012, Expiry date Dec. 2013, 
NAFDAC Reg. No. 04 -275. Manufactured by 
Beijing Novartis Pharma Ltd, Beijing China. 
 
Brand B (Lumartem® tablets); Batch No.FD2011, 
Manufac. date Jan. 2012, Expiry date Dec. 2013, 
NAFDAC Reg. No. A4 -4845. Manufactured by 




The spectrophotometric analysis of artemether in 
samples was carried out after derivatization. 
Derivatization was done by treating samples with 
1 M ethanolic hydrochloride and heated at 60 oC 
for 3 h, this enabled the formation of acid 
decomposition product described as α, β- 
unsaturated decalone [6-8] which absorbs at 254 
nm. 
 
Phase solubility studies and determination of 
apparent stability constants (Kc) 
 
Phase solubility behavior was studied according 
to the method proposed by Higuchi and Connors 
[9]. An excess of the drug (200 mg) was added to 
20 mL portions of distilled water in six conical 
flasks, each containing variable amounts of 2-
HP- β -CD (0, 3, 6, 9, 12, and 15 x10-3  
moles/Liter). The solutions were shaken on a 
flask shaker (Grant OLS 200, Cambridge – 
England) for 24 h at 37 ± 2 oC, filtered and 100 
mL of 1 M ethanolic HCl added to 2 mL of each 
filtrate and shaken for 5 s. This was heated for 3 
h at 60 oC and allowed to cool to room 
temperature. Their absorbance was taken at 254 
nm wavelength. 
 
The solubility of the artemether in every 2-HP-β-
CD solution was calculated and phase solubility 
diagram was drawn between the solubility of 
artemether and different concentrations of 2-HP-
β-CD. 
 
The stability constant (Kc) of artemether:2-HP-β-
CD complex was calculated using Higuchi and 




 ………….. (1) 
 
Preparation of inclusion complexes in solid 
state 
 
This was prepared using artemether and 2-
hydroxypropyl-β-cyclodextrin in different molar 
ratios (1:1, 1:2 and 1:3 M). First, a small quantity 
of 50 % ethanol was added into cyclodextrin in a 
glass mortar and triturated until a paste was 
obtained. Then, the drug was added into the 
paste and kneaded for 1 h. The product was then 
air dried at room temperature (28 oC) for 24 h, 
pulverized, passed through a sieve of size 90 µm 
and stored in a desiccator over fused calcium 
chloride. 
 
Differential scanning calorimetry 
 
Thermograms of pure artemether, 2-
hydroxypropyl-β-cyclodextrin and inclusion 
complex were recorded by heating the samples 
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at a temperature range of 30 to 300 oC at a rate 
of 10 °C/min.  
 
Fourier transform-infrared spectroscopy (FT-
IR) 
 
The FT-IR spectra of artemether, its complexes, 
and 2-hydroxypropyl-β-cyclodextrin were 
obtained by KBr pellet method using FTIR 
spectrophotometer (SHIMADZU FTIR 8400S) 
over the range 500 - 4,500 cm–1.  
 
Formulation of artemether-cyclodextrin 
inclusion complex tablets 
 
Inclusion complex of artemether-cyclodextrin of 
molar ratio 1:1 was used for the preparation of 
tablets. The complex of artemether: 2-HP-β-CD 
containing the equivalent of 20 mg artemether 
was compressed into tablets by direct 
compression method. The complex, maize starch 
and microcrystalline cellulose were mixed 
together after which talc and magnesium 
stearate were added and further mixed for 5 min. 
The mixture was then compressed into tablets 
(using a compression force of 10.5 metric ton 
and a punch size of 12.5 mm). The tablets were 
evaluated for thickness, diameter, weight 
uniformity, crushing strength, friability, 
disintegration and dissolution time. 
 
In vitro dissolution studies for artemether-CD 
inclusion complex tablets 
 
In vitro dissolution of artemether inclusion 
complex tablets containing 20 mg of artemether 
was studied in Erweka dissolution apparatus 
(Erweka DT, Germany). Five hundred millilitres 
of simulated gastric fluid was used as dissolution 
medium. The basket was rotated at 50 rpm and 
the temperature of dissolution medium 
maintained at 37.0 ± 0.5 ºC. Five millilitre 
aliquots were withdrawn at predetermined 
intervals (5, 10, 15, 30, 45, 60, 75, 90, 105 and 
120 min) and filtered using Whatman filter paper 
no. 41. At each interval, withdrawn volume was 
replaced with a fresh quantity of dissolution 
medium. After suitable dilution, the withdrawn 
samples were derivatized by treating with 1 M 
ethanolic hydrochloride and heated at 60 oC for 3 
h, then analyzed spectrophotometrically at λmax 
of 254 nm. The percentage amount of artemether 
released was calculated and plotted against time. 
This was compared with both the dissolution 
profile of the pure artemether and the 
commercial products. 
      
Statistical analysis 
 
The data generated from the various determina- 
tions were analyzed using SPSS 
20.0 software (SPSS, Chicago, IL, USA) and are 
presented as mean ± standard deviation (SD). 
The differences between the data sets were 
determined using one-way analysis of variance 





Phase solubility  
  
The phase solubility diagram gave a straight line 
with R2 value of 0.9963 and y = 0.0014x + 7E-06. 
The phase solubility diagram for the formed 
complexes in water at 37 oC indicated a linear 
curve soluble complexes system (referred to as 
the AL system) following the Higuchi and Connors 
classification [11]. A stability constant (Kc) value 




The DSC thermograms of the pure drug, the 2-
hydroxypropyl-β-cyclodextrin and the prepared 




Figure 1: DSC thermograms of pure artemether 
sample (1), 2-hydroypropyl-β-cyclodextrin (5), 
artemether-2-HP-β-CD (1:1) complex (4), artemether-
2-HP-β-CD (1:2) complex (2), artemether-2-HP-β-CD 
(1:3) complex (3) 
 
The DSC thermogram of pure artemether 
exhibits a sharp endothermic peak at 89.6 oC and 
an exothermic peak at 180 oC, which is 
consistent with the findings of Yang et al [12]. 
The 2-hydroxypropyl-β-cyclodextrin exhibited a 
typical broad endothermic peak between 50 - 
100 °C, which attained a maximum at 87.2 oC, 
consistent with the findings of Liu and Zhu [13].  
The DSC thermograms of the inclusion 
complexes exhibited mark decrease in intensity 
to even complete disappearance of the 
artemether endothermic and exothermic peaks. 
Changes in the exothermic peak (corresponding 
to its decomposition temperature) ranging from a 
Yahaya et al 
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marked reduction in intensity to a complete 
disappearance suggest that the 2-HP-β-CD-
artemether complex is more thermally stable 
than the artemether alone and this further 
supports the fact that inclusion complex 




The FT-IR spectra of the pure artemether and its 
inclusion complexes over the frequency range of 
500 – 4500 cm-1 are given in Figure 2. The 
characteristic FT-IR peaks of the pure artemether 
occurred at 3198.08 cm-1 due to O-H stretching 
vibration, C-H stretching at 2932.86 cm-1, C-H 
bending at 1020.38 cm-1, C-O bending at 
1020.38 cm-1, C-O-O-C bending vibration at 
1195.95 cm-1, O-O-C stretching at 857 cm-1 and 
O-O stretching at 746 cm-1 respectively. These 
values are comparable to those earlier reported 




Figure 2: FT-IR spectrum of pure artemether sample 
(A), 2-hydroypropyl-β-cyclodextrin (B), artemether-2-
HP-β-CD (1:1) complex (C), artemether-2-HP-β-CD 
(1:2) complex (D) and artemether-2-HP-β-CD (1:3) 
complex (E) 
 
In the FT-IR spectra of 1:1 M inclusion complex, 
the bands of the pure drug due to O-H bending 
and C-O bending vibration were shifted to higher 
frequencies of 3396 and 1037.74 cm-1 
respectively while those due to C-H stretching 
and C-H bending were shifted to lower 
frequencies 2930.93 and 1373.36 cm-1 with 
marked decrease in intensity. In 1:2 M molar 
inclusion spectra the decrease in peak intensity 
was more compared to what was observed in the 
1:1 M inclusion complex. In addition, peaks at 
3198.08 and 1020.38 cm-1 were shifted to higher 
frequencies and appeared at 3424 and 1043.32 
cm-1 respectively. Those at 2932 and 1449.55 
cm-1 were shifted to lower frequencies and 
appeared at 2928.04 and 1368.54 cm-1 
respectively. In addition, there was a 
disappearance of bands at 4594.59, 4241.61, 
4066.08 and 3862.58 cm-1.  
 
For the 1:3 M inclusion complex spectra, peaks 
at 3198.08 and 1020.38 cm-1 were equally shifted 
to higher frequencies while those at 2932.86 and 




The properties for the commercial and prepared 
tablets of cyclodextrin-artemether inclusion 
complex are given in Table 1. 
 
For the prepared inclusion complex tablet; the 
crushing strength was in the range of 10.0 – 10.5 
kg/F, the percentage friability was 0.048 which is 
less than 1 % (fulfilling the official requirements), 
the drug content was 95.5 % and the 
disintegration time was 9.28 min which is within 
Pharmacopoeia limits (15 min for uncoated 
tablets), [16]. The mean weight of 402.85 mg 
was   within   the   Pharmacopoeia  limits,  which 
specifies that for tablets weight > 250 mg, ± 5 % 
weight variation is allowed [16]. The inclusion 
complex tablets prepared, therefore, fall within 




Table 1: Tablet characteristics of commercial and formulated artemether tablets (mean ± SEM) 
 
 






Thickness (mm) 3.22±0.01 3.52±0.01 3.54±0.02 0.922 
Uniformity of weight (mg) 240.65±0.33 344.95±5.17 402.85±1.39 0.774 
Diameter (mm) 8.88±0.02 10.09±0.03 12.07±0.02 0.612 
Crushing strength (kg/F) 11.7±0.12 7.40±0.40 10.90±0.20 0.193 
Drug content (%) 98.5±0.00 97.00±0.03 95.50±0.07 0.917 
Disintegration time (Min) 3.37±0.03 3.30±0.25 9.28±0.04 0.003** 
Friability (%) 0.048±0.000 0.083±0.001 0.058±0.001 0.074 
** indicates significance at 5% level (P<0.05) 
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Figure 3: Dissolution profiles of pure artemether (◊), 
brand A (∆), brand B (■) and inclusion complex (1:1) 




The dissolution profile of the inclusion complex 
(1:1 M) tablet, marketed tablets (brands A and B) 
and the pure drug sample in simulated gastric 




The phase solubility diagram showed that the 
solubility of artemether increased as the 
concentration of 2-hydroxypropyl-β-cyclodextrins 
increased. It further shows that each complex 
contains only one molecule of the complexing 
agent. Because the linear host-guest correlation 
obtained had a slope less than one (1) it suggest 
that the stoichiometry of the complexes is 1:1 
(mol/mol) artemether-2-HP-β-CD [17]. 
 
The value of the stability constant (Kc) falls within 
the range of 50-2000 M,-1 suggesting a favorable 
interaction that may contribute to the improved 
dissolution of hydrophobic drugs occurred 
[17,18]. It has been reported that when a guest 
molecule is incorporated in CD cavity, its 
physicochemical properties are usually modified 
[3,19,20].  
 
Earlier reports have shown that inclusion of 
drugs into cyclodextrin temporarily locked or 
caged the drug within the host cavity, giving rise 
to beneficial modifications like solubility 
enhancement, stabilization of labile guest 
molecule against oxidation, visible or UV light, 
heat and so forth [21]. These observations, 
therefore, clearly indicate strong evidence of 
inclusion of the drug into the cyclodextrin cavity.  
All inclusion complexes (1:1, 1:2 and 1:3 M) 
exhibited pronounced enhancement with 
comparable values of dissolution rate; therefore, 
inclusion complex of molar ratio 1:1 was used for 
the preparation of tablets since it contains lesser 
amount of cyclodextrin than complexes of molar 
ratios 1:2 and 1:3. The prepared tablets were of 
good properties and did not exhibit chipping, 
capping or sticking. The tested commercial 
tablets equally conformed to the compendial 
specifications for uniformity of weight, 
percentage friability and disintegration time.  
 
The dissolution rates of the inclusion complex 
tablets (from inclusion complex of 1:1 M ratio) 
were found to be higher than that of the 
commercial brands. Tablets formulated from the 
inclusion complexes exhibited 3.9-fold, 1.8-fold, 
and 1.6-fold increases, respectively over the pure 
sample and the commercial brands A and B in 
the amount of drug released in 15 min. The 
amount of artemether dissolved after 45 min (t45) 
from inclusion complex tablets was 93.1 %, while 
corresponding values of 68 and 67 %, 
respectively, were dissolved from A and B. The 
increased dissolution rate of artemether - 
cyclodextrin inclusion complexes may be 
attributable to improvement in drug wettability, 
decrease in drug crystallinity, increase in 
hydrophilicity or a reduction in the interfacial 
tension between the drug and the dissolution 
medium due to the surfactant-like properties of 
CDs [22].  
CONCLUSION 
 
Molecular inclusion complex formation between 
2-HP-β-CD and artemether has been confirmed 
with the inclusion complex displaying enhanced 
solubility of artemether in distilled water. Tablets 
formulated from 1:1 M ratio of the artemether-2-
HP-β-CD complex have higher dissolution rate 
than the selected commercial artemether tablets. 
Thus, the developed artemether/2-HP-β-CD 
complex can be further explored to develop 
artemisinin-combination therapies with enhanced 
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